Phaseline

Targets › PRL3

PRL3 (Protein tyrosine phosphatase type IVA 3): drug programs, companies and trials

1 program from 1 company in 5 trials: 3 Phase 2, 2 Phase 1; Oncology, Ophthalmology; next expected readout Dec 2026.

Protein tyrosine phosphatase which stimulates progression from G1 into S phase during mitosis. Enhances cell proliferation, cell motility and invasive activity, and promotes cancer metastasis. (UniProt, O75365)

Open in Phaseline: the race on PRL3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Intra-IMMUSG PtePRL3-zumab
Humanized monoclonal antibody targeting phosphatase of regenerating liver-3 (PRL3)
PRL3Phase 2Advanced Malignant Solid Tumor; Solid Tumor; Advanced Solid Cancers; Neovascular Age Related Macular Degeneration …Dec 2026

Conditions

Advanced Malignant Solid Tumor (1) Solid Tumor (1) Advanced Solid Cancers (1) Neovascular Age Related Macular Degeneration (1) Advanced Solid Tumors (1)

Modalities

antibody (1)

Companies

Intra-IMMUSG Pte (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.